Anebulo Pharmaceuticals, Inc. 8-K

What Happened Anebulo Pharmaceuticals, Inc. (ANEB) announced that its Board approved a voluntary delisting of the company’s common stock from The Nasdaq Capital Market and plans to terminate SEC registration to suspend its reporting obligations. The Board approved the action on February 5, 2026; the company issued a press release on February 6, 2026. Anebulo notified Nasdaq and intends to file a Form 25 with the SEC on or about February 17, 2026; the delisting is expected to become effective on February 27, 2026 (10 days after filing Form 25). The company also intends to file a Form 15 on or about February 27, 2026 certifying it has fewer than 300 shareholders of record, and upon filing Form 15 its obligation to file periodic reports with the SEC will be immediately suspended.

Key Details

• Board approval date: February 5, 2026; press release issued February 6, 2026.
• Expected Form 25 filing: on or about February 17, 2026; delisting effective ~February 27, 2026 (10 days after Form 25 filing).
• Expected Form 15 filing: on or about February 27, 2026, certifying fewer than 300 shareholders of record.
• Immediate effect upon Form 15: suspension/termination of Anebulo’s obligation to file periodic SEC reports.

Why It Matters Delisting from Nasdaq and deregistration with the SEC mean Anebulo will stop filing regular public reports (like 10-Ks and 10-Qs) once the Form 15 is filed. For investors, that reduces the amount of ongoing public financial disclosure and may affect the liquidity and transparency of the company’s shares. Investors who hold or are considering ANEB shares should note these dates and monitor company communications for next steps and any information on how the stock will be traded after delisting.